Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.

CONCLUSIONS: Although historically older patients have not been routinely considered for enrollment in phase 1 trials, our data demonstrates similar toxicity profiles to that of younger patients and 63% clinical benefit rate. Thus, with careful selection, patients ≥70 should be considered when facing recurrent or refractory gynecologic cancer. PMID: 29605046 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29605046?dopt=Abstract

Source: Gynecologic Oncology - April 1, 2018 Category: Cancer & Oncology Authors: Buechel M, McGinnis A, Vesely SK, Wade KS, Moore KN, Gunderson CC Tags: Gynecol Oncol Source Type: research